You are here: Home » Current Affairs » Coronavirus » News
Business Standard

EU to buy up to 300 million doses of Pfizer-BioNTech Covid-19 vaccine

The European Commission will sign a deal to secure up to 300 million doses of the experimental coronavirus vaccine developed by BioNTech and Pfizer

Topics
Pfizer | Coronavirus Vaccine | Coronavirus Tests

AP  |  Brussels 

Coronavirus, vaccine, covid, drugs, clinical trials
Representative photo of a vaccine

The European Commission will sign a deal to secure up to 300 million doses of the experimental vaccine developed by BioNTech and

Ursula von der Leyen, the president of the EU's executive arm, said the commission will authorize the deal on Wednesday after working tirelessly to secure doses of potential vaccines in recent months.

This is the most promising vaccine so far, von der Leyen said. Once this vaccine becomes available, our plan is to deploy it quickly, everywhere in Europe. said Monday that early results from the vaccine suggests the shots may be a surprisingly robust 90% effective at preventing COVID-19.

The European Commission had already secured three other deals with pharmaceutical companies allowing its 27 member states to buy nearly one billion doses of a potential vaccine.

And more will come. Because we need to have a broad portfolio of vaccines based on different technologies, von der Leyen said. We have already started working with member states to prepare national vaccination campaigns. We are almost there. In the meantime, let us be prudent, and stay safe.

The commission said once a vaccine is ready, member states should have access to it at the same time, and give priority to groups including healthcare workers and people over 60 years, as well as people with health conditions making them more vulnerable.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, November 11 2020. 09:21 IST
RECOMMENDED FOR YOU